April
6,
2018
Dr. Alita Miller
Head of Biology
Entasis Therapeutics
Hosted by: AAPS UW-Madison Student Chapter
Antibiotic resistance is a serious public health crisis. Antibacterial regulatory guidelines have been recently updated to allow for more streamlined development of narrow-spectrum, precision therapies to treat highly problematic, multidrug-resistant bacterial infections. Accordingly, various strategies are being pursued to develop candidate agents for narrower-than-usual or specific pathogen-directed indications. Entasis Therapeutics has embraced this new paradigm as exemplified by two of its current clinical programs: (1) zoliflodacin, a novel oral antibiotic for the treatment of uncomplicated gonorrhea and (2) sulbactam-ETX2514, a novel combination agent targeting carbapenem-resistant Acinetobacter baumannii. Details around the discovery and development of each of these candidates will be presented.
Reception to follow
